DelRicht Research

We were excited to see the recent announcement from Roche on the unprecedented Phase III results for fenebrutinib, a potential first-in-class, high-efficacy oral BTK inhibitor being studied in both relapsing and primary progressive multiple sclerosis (PPMS). The FENhance 2 and FENtrepid trials demonstrated significant reductions in relapse rates for RMS and a slowing of disability progression in PPMS comparable to the current standard of care. These findings represent meaningful progress for individuals living with MS, particularly for those with progressive disease, where effective treatment options remain limited. We are especially proud to recognize Dr. Lesley Saketkoo, whose long-standing contributions to neuro-immunology, complex autoimmune disease, and progressive inflammatory disorders, including her work in MS, sarcoidosis, and interstitial lung disease, continue to support advancements in areas with profound unmet need. Her commitment to multidisciplinary, patient-centered research helps propel studies like these forward and ensures that new therapies have the potential to reach the patients who need them most. A sincere thank-you to the global investigators, coordinators, and research teams involved in these pivotal studies. Their continued dedication is essential in driving progress across challenging conditions such as multiple sclerosis. Read Roche’s full press release here: https://lnkd.in/gRaF2vjz

Big news in infectious disease and antiviral innovation! Merck has announced a definitive agreement to acquire Cidara Therapeutics in a $9.2B transaction that expands and diversifies Merck’s pipeline with CD388, a potentially first-in-class, long-acting, strain-agnostic antiviral designed to prevent influenza in high-risk individuals. Rob Davis, Merck’s Chairman & CEO, emphasized how the acquisition reflects Merck’s science-led business development strategy, building on Cidara’s remarkable progress and accelerating the path forward for CD388. CD388 is currently in the Phase 3 ANCHOR study, following compelling Phase 2b results and both Breakthrough Therapy and Fast Track designations from the FDA, underscoring its potential to become a transformative option for influenza prevention. Learn more in the official announcement here: https://lnkd.in/eRX2DqWy Congratulations to Merck and Cidara on this exciting milestone in advancing long-acting antiviral innovation! #ClinicalResearch #Influenza #AntiviralTherapies #DrugDevelopment #Biopharma #Merck #Cidara

150% of Enrollment Goal Achieved in a Phase 3 Migraine Trial! Four DelRicht Research sites in Atlanta, Gulfport, New Orleans, and Tulsa collectively enrolled 36 participants, delivering 150% of our expected goal in a complex Phase 3 migraine program. With an average of just 3.5 days from activation to first patient screened, and Dr. Robert Springer recognized as the #2 top enroller studywide, this performance highlights the efficiency and reliability sponsors can expect from DelRicht’s embedded site network. From verified medical record workflows to proactive eDiary compliance and participant support systems, our teams continue to demonstrate what operational precision and patient engagement can achieve in large-scale neurology trials. Huge thank you to our participating investigators: Dr. Robert Springer | Atlanta, GA Dr. Sean Kerby | Gulfport, MS Dr. Patrick Dennis | New Orleans, LA Dr. Melita Tate | Tulsa, OK Read the full case study: https://lnkd.in/gkstcgFA #ClinicalResearch #Migraine #Neurology #ClinicalTrials #DataQuality #SitePerformance #DelRichtResearch #MovingMedicineForward

Our team is still buzzing from a conversation that reminded us not just what we do, but why we do it. We had the recent privilege of welcoming Stacy Hurt 🌻, Chief Patient Officer at Parexel, and Cheri Savercool Morgan, Parexel’s Community Alliance Network Relationship Manager, to our all-team meeting. Together, they delivered a powerful and grounding discussion that resonated deeply across our team. Stacy’s story reframed patient centricity as something lived, not just discussed, and reminded us that behind every visit, datapoint, and milestone is a patient in need of hope, a family in need of care. She spoke of the reality patients face: the procedures, the travel, the fear of being a “guinea pig.” And she reinforced the collective responsibility we share, as sites, CROs, and sponsors, to design studies that fit into a patient’s life. “Patients are people first. They don’t fail treatments, treatments fail patients.” - Stacy Hurt 🌻 From our team’s perspective, the impact of their presentation was immediate and deeply felt: "Hearing Stacy's perspective and experience - in the industry, as caregiver, and as patient... just wow. If anyone truly understands what is impactful for patients and how important it is that we continue to strive to support our patients in every way possible, it is her." - Justin Colbert “We have worked with Parexel on multiple studies over the past three years at our site. Communication has always been excellent, and they are so helpful! The team at Parexel are not only professionals but also great people!” - Brittany Bolton Hearing Stacy and Cheri speak side-by-side was a masterclass in what true collaboration looks like, science meeting empathy, process meeting purpose, performance meeting heart. We’re deeply grateful to the Parexel team for the partnership, trust, and shared vision that continues to move medicine forward. Together, we’re redefining what patient-centered research can be. #Parexel #DelRichtResearch #PatientCentricity #ClinicalResearch #Partnership #LeadershipWithHeart #MovingMedicineForward

Congrats to Dr. Patrick Dennis and our New Orleans site team for their outstanding performance in a recent Phase 2 hypertension trial! Led by Dr. Dennis and Site Manager Emily Krambeck, the team’s focus, precision, and commitment to patient engagement earned recognition as the top enrolling site studywide, contributing 24.4% of total study enrollment. Performance Highlights: -  Top enrolling site studywide -  44 participants enrolled (24.4% of total enrollment) -  First patient screened within 48 hours of activation This achievement reflects the power of DelRicht’s embedded site model, driven by operational speed, proactive communication, and a commitment to advancing care options for patients living with hypertension. Read the full case study on our website!  https://lnkd.in/gjiSddHw #ClinicalResearch #Hypertension  #ClinicalTrials #SitePerformance #ResearchExcellence #DelRichtResearch #MovingMedicineForward

Congrats to Dr. Ira Thorla, Dr. Zachary Eyre, and their incredible site teams for outstanding performance in a Phase 2 hidradenitis suppurativa (HS) trial! Our Baton Rouge and Atlanta sites led the way: first to activate studywide, first patient randomized globally, and 247% of our enrollment goal delivered. Performance Highlights: • First to Activate & Randomize • 14 participants enrolled across two sites • 247% of the expected goal achieved • Dr. Thorla recognized as a Top Enroller studywide • Dr. Eyre’s site was activated within just 44 days of award This is the power of DelRicht’s embedded site model, operational speed, protocol precision, and patient-centered execution. Huge thanks to our site managers, Hilary Kingsley & Maddie LaQua, for the day-to-day leadership that made this possible. Read the full case study: https://lnkd.in/gMXBAXw6 #ClinicalResearch #Dermatology #HidradenitisSuppurativa #ClinicalTrials #SitePerformance #DelRichtResearch #MovingMedicineForward

DelRicht Research continues to advance innovation in vitiligo treatment! Over the past five years, our network has supported 9 vitiligo trials, with 4 sites ranking among top enrollers across multiple Phase I-IV programs. Our teams have proudly contributed to one FDA approval, Opzelura® (ruxolitinib), marking a major step forward for patients and providers seeking effective treatment options. From early feasibility to long-term follow-up, our investigators and site staff bring deep expertise in dermatology and autoimmune research, ensuring exceptional data quality and participant care across every study. Explore our full Vitiligo Performance Summary here: https://lnkd.in/gcdWGRqB #VitiligoResearch #DermatologyTrials #ClinicalResearch #SiteExcellence #DelRichtResearch

A HUGE congratulations to the exceptional teams across 16 participating sites for their outstanding contributions in a pivotal US-based Phase 3 gout trial! Together, our investigators enrolled 297 participants, more than double our goal and representing nearly 40% of the entire study population. Performance highlights include: - 7 DelRicht Research sites ranked among the national Top 10 enrollers - 13 of 16 sites placed within the Top 20 overall - Three investigators (Dr. Amy Roberts, Dr. Rachael Holliday, M.D., Dr. Robert Springer) led enrollment for participants with tophaceous gout, underscoring our ability to deliver results in complex patient populations We’re incredibly proud of our principal investigators and site teams for their dedication to operational excellence, patient engagement, and advancing treatment options in rheumatology. Read the full case study on our website: https://lnkd.in/gQGWyz-A #ClinicalResearch #Gout #Rheumatology #ClinicalTrials #PatientEnrollment #DelRichtResearch #MovingMedicineForward

A big congratulations to Dr. Ira Thorla, Dr. Robert Springer, and their outstanding site teams for their remarkable performance in a pivotal US-based Phase 2/3 trial for androgenetic alopecia (AGA)! Together, our two participating sites achieved 310% of the expected enrollment goal, setting a new benchmark for excellence in dermatology research. Performance highlights include: - 70 participants enrolled across two DelRicht Research sites - Exceeded the sponsor’s target enrollment goal by 210% - Dr. Robert Springer enrolled 39 participants (355% of the expected goal) - Patient-centered education strategies that eased concerns about protocol requirements and supported strong participation We’re incredibly proud of our investigators and site staff for their dedication to operational precision, patient engagement, and advancing treatment options in dermatology. Read the full case study on our website: https://lnkd.in/gcHAXCbc #ClinicalResearch #Dermatology #AndrogeneticAlopecia #ClinicalTrials #PatientEnrollment #DelRichtResearch #MovingMedicineForward

We’re pleased to recognize Incyte on the U.S. FDA approval of Opzelura® (ruxolitinib) cream 1.5% for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in children as young as two years old. This milestone makes Opzelura the first topical JAK inhibitor approved in the U.S. for pediatric AD, offering families a much-needed non-steroidal treatment option. As Bill Meury, Chief Executive Officer of Incyte, shared, this approval represents an important advance in addressing the daily challenges faced by children and families living with AD. DelRicht Research is proud to have supported this advancement through two of our participating sites, where our investigators and coordinators partnered closely with patients and families to ensure high-quality trial conduct. Their commitment underscores the vital role community-based research plays in bringing new therapies to life. We celebrate the many collaborators, sponsors, CRO partners, site teams, and especially trial participants, whose dedication helped make this approval possible. Read Incyte’s full announcement here: https://lnkd.in/gbw9jr5G #ClinicalResearch #FDAApproval #AtopicDermatitis #Dermatology #Opzelura #DelRichtResearch